Overview Dividends

(BRKR) Bruker - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1167941087

Magnetic Resonance Instruments, Mass Spectrometers, X-Ray Systems, Microscopy Tools, Molecular Diagnostics

BRKR EPS (Earnings per Share)

EPS Growth (3Y CAGR): -16.55%
EPS Trend (3Y Correlation): -50.1%

BRKR Revenue

Revenue Growth (3Y CAGR): 7.33%
Revenue Trend (3Y Correlation): 70.3%

Risk via 10d forecast
Volatility	38.3%
Value at Risk 5%th	60.8%
Relative Tail Risk	-3.46%

Reward TTM
Sharpe Ratio	-0.35
Alpha	-40.61

Character TTM
Hurst Exponent	0.401
Beta	1.136
Beta Downside	1.151

Drawdowns 3y
Max DD	68.72%
Mean DD	29.24%
Median DD	28.44%

Description: BRKR Bruker November 05, 2025

Bruker Corporation (NASDAQ: BRKR) designs, manufactures, and sells a broad array of scientific instruments and analytical solutions across the United States, Europe, Asia-Pacific, and other international markets. The firm operates through four primary segments-Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies-covering magnetic-resonance spectroscopy, pre-clinical imaging, mass spectrometry, MALDI-Biotyper microbial identification, portable X-ray fluorescence, atomic-force microscopy, and superconducting-material equipment.

In fiscal 2023 Bruker reported revenue of roughly $2.2 billion, up about 5 % year-over-year, with an operating margin near 13 % and research-and-development spending representing roughly 12 % of sales. The life-sciences tools sector is projected to grow at a 6 % compound annual growth rate through 2028, driven by expanding biotech R&D pipelines, increased government funding for genomics and proteomics, and a shift toward high-throughput, multi-omics platforms-trends that directly benefit Bruker’s BSI and diagnostic product lines.

Given Bruker’s diversified product mix, solid cash generation, and exposure to fast-growing scientific-instrument markets, a deeper quantitative view of its valuation metrics can be valuable; the ValueRay platform provides a data-driven analysis that may help you refine your investment thesis.

BRKR Stock Overview

Market Cap in USD	6,067m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	2000-08-04
Return 12m vs S&P 500	-33.0%
Analyst Rating	3.86 of 5

BRKR Dividends

Dividend Yield	0.48%
Yield on Cost 5y	0.41%
Yield CAGR 5y	5.74%
Payout Consistency	96.5%
Payout Ratio	11.6%

BRKR Growth Ratios

CAGR 3y	-14.15%
CAGR/Max DD Calmar Ratio	-0.21
CAGR/Mean DD Pain Ratio	-0.48
Current Volume	1776.2k
Average Volume	2612.1k

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-20.9m TTM) > 0 and > 6% of Revenue (6% = 206.3m TTM)

FCFTA -0.00 (>2.0%) and ΔFCFTA -2.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 31.48% (prev 26.82%; Δ 4.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.01 (>3.0%) and CFO 94.3m > Net Income -20.9m (YES >=105%, WARN >=100%)

Net Debt (1.75b) to EBITDA (289.4m) ratio: 6.06 <= 3.0 (WARN <= 3.5)

Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (151.8m) change vs 12m ago -0.13% (target <= -2.0% for YES)

Gross Margin 47.36% (prev 48.95%; Δ -1.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 54.81% (prev 53.02%; Δ 1.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.15 (EBITDA TTM 289.4m / Interest Expense TTM 64.4m) >= 6 (WARN >= 3)

Altman Z'' 2.98

(A) 0.17 = (Total Current Assets 2.35b - Total Current Liabilities 1.27b) / Total Assets 6.43b

(B) 0.37 = Retained Earnings (Balance) 2.35b / Total Assets 6.43b

(D) 0.58 = Book Value of Equity 2.27b / Total Liabilities 3.94b

Total Rating: 2.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 41.15

1. Piotroski 2.0pt = -3.0

2. FCF Yield -0.14% = -0.07

3. FCF Margin -0.31% = -0.12

4. Debt/Equity 0.84 = 2.16

5. Debt/Ebitda 6.06 = -2.50

6. ROIC - WACC (= -6.33)% = -7.91

7. RoE -1.07% = -0.18

8. Rev. Trend 70.34% = 5.28

9. EPS Trend -50.05% = -2.50

What is the price of BRKR shares?

As of November 16, 2025, the stock is trading at USD 41.62 with a total of 1,776,193 shares traded.
Over the past week, the price has changed by +4.23%, over one month by +13.96%, over three months by +23.91% and over the past year by -23.25%.

Is Bruker a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Bruker (NASDAQ:BRKR) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 41.15 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BRKR is around 38.04 USD . This means that BRKR is currently overvalued and has a potential downside of -8.6%.

Is BRKR a buy, sell or hold?

Bruker has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy BRKR.

Strong Buy: 5
Buy: 2
Hold: 7
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BRKR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	47.8	14.9%
Analysts Target Price	47.8	14.9%
ValueRay Target Price	42.2	1.3%

BRKR Fundamental Data Overview November 11, 2025

Market Cap USD = 6.07b (6.07b USD * 1.0 USD.USD)
P/E Forward = 13.8313
P/S = 1.7642
P/B = 2.9293
P/EG = 3.64
Beta = 1.198
Revenue TTM = 3.44b USD
EBIT TTM = 74.3m USD
EBITDA TTM = 289.4m USD
Long Term Debt = 2.06b USD (from longTermDebt, last fiscal year)
Short Term Debt = 24.3m USD (from shortTermDebt, last quarter)
Debt = 2.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.75b USD (from netDebt column, last quarter)
Enterprise Value = 7.82b USD (6.07b + Debt 2.05b - CCE 295.0m)
Interest Coverage Ratio = 1.15 (Ebit TTM 74.3m / Interest Expense TTM 64.4m)
FCF Yield = -0.14% (FCF TTM -10.6m / Enterprise Value 7.82b)
FCF Margin = -0.31% (FCF TTM -10.6m / Revenue TTM 3.44b)
Net Margin = -0.61% (Net Income TTM -20.9m / Revenue TTM 3.44b)
Gross Margin = 47.36% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 44.88% (prev 44.88%)
Tobins Q-Ratio = 1.22 (Enterprise Value 7.82b / Total Assets 6.43b)
Interest Expense / Debt = 0.98% (Interest Expense 20.0m / Debt 2.05b)
Taxrate = 19.42% (-14.1m / -72.6m)
NOPAT = 59.9m (EBIT 74.3m * (1 - 19.42%))
Current Ratio = 1.85 (Total Current Assets 2.35b / Total Current Liabilities 1.27b)
Debt / Equity = 0.84 (Debt 2.05b / totalStockholderEquity, last quarter 2.43b)
Debt / EBITDA = 6.06 (Net Debt 1.75b / EBITDA 289.4m)
Debt / FCF = -165.5 (out of range, set to none) (Net Debt 1.75b / FCF TTM -10.6m)
Total Stockholder Equity = 1.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.32% (Net Income -20.9m / Total Assets 6.43b)
RoE = -1.07% (Net Income TTM -20.9m / Total Stockholder Equity 1.96b)
RoCE = 1.85% (EBIT 74.3m / Capital Employed (Equity 1.96b + L.T.Debt 2.06b))
RoIC = 1.49% (NOPAT 59.9m / Invested Capital 4.02b)
WACC = 7.82% (E(6.07b)/V(8.12b) * Re(10.20%) + D(2.05b)/V(8.12b) * Rd(0.98%) * (1-Tc(0.19)))
Discount Rate = 10.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.97%
Fair Price DCF = unknown (Cash Flow -10.6m)
EPS Correlation: -50.05 | EPS CAGR: -16.55% | SUE: 2.38 | # QB: 1
Revenue Correlation: 70.34 | Revenue CAGR: 7.33% | SUE: 0.69 | # QB: 0

Additional Sources for BRKR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle